Allogeneic stem-cell transplantation in HIV-1-infected patients with high-risk hematological disorders
Conclusion:
Allogeneic HSCT is an effective therapy for high-risk hematological malignancies in patients with HIV infection, and long-term HIV suppression with combination antiretroviral therapy is feasible. However, drug interactions with antiretroviral agents, occurrence of GVHD, and frequent infectious complications account for a complex procedure in this population. Selected HIV-infected patients with hematologic malignancies should be considered for allo-HSCT when indicated, in experienced centers.
Source: AIDS - Category: Infectious Diseases Tags: CLINICAL SCIENCE Source Type: research
More News: Aspergillosis | Cancer & Oncology | Hematology | HIV AIDS | Infectious Diseases | Science | Spain Health | Stem Cell Therapy | Stem Cells | Toxicology | Transplants | Tuberculosis